DK3515910T3 - 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma - Google Patents

5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma Download PDF

Info

Publication number
DK3515910T3
DK3515910T3 DK17772381.4T DK17772381T DK3515910T3 DK 3515910 T3 DK3515910 T3 DK 3515910T3 DK 17772381 T DK17772381 T DK 17772381T DK 3515910 T3 DK3515910 T3 DK 3515910T3
Authority
DK
Denmark
Prior art keywords
underivatives
isoindol
phosphatidylinositol
ylamino
thiazol
Prior art date
Application number
DK17772381.4T
Other languages
Danish (da)
English (en)
Inventor
Matthew Perry
Konstantinos Karabelas
Mickael Mogemark
Peter Bold
Christian Tyrchan
Antonios Nikitidis
Jens Petersen
Ulf Börjesson
Original Assignee
Astrazeneca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca filed Critical Astrazeneca
Application granted granted Critical
Publication of DK3515910T3 publication Critical patent/DK3515910T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17772381.4T 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma DK3515910T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398006P 2016-09-22 2016-09-22
PCT/EP2017/073916 WO2018055040A1 (en) 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma

Publications (1)

Publication Number Publication Date
DK3515910T3 true DK3515910T3 (da) 2020-08-31

Family

ID=59966739

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17772381.4T DK3515910T3 (da) 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma

Country Status (36)

Country Link
US (2) US10961236B2 (OSRAM)
EP (1) EP3515910B1 (OSRAM)
JP (1) JP6765516B2 (OSRAM)
KR (1) KR102226098B1 (OSRAM)
CN (1) CN109715623A (OSRAM)
AR (1) AR109706A1 (OSRAM)
AU (1) AU2017331940B2 (OSRAM)
BR (1) BR112019004719A2 (OSRAM)
CA (1) CA3036304A1 (OSRAM)
CL (1) CL2019000707A1 (OSRAM)
CO (1) CO2019003440A2 (OSRAM)
CR (1) CR20190200A (OSRAM)
CY (1) CY1123346T1 (OSRAM)
DK (1) DK3515910T3 (OSRAM)
DO (1) DOP2019000073A (OSRAM)
EA (1) EA036176B1 (OSRAM)
EC (1) ECSP19027780A (OSRAM)
ES (1) ES2818583T3 (OSRAM)
HR (1) HRP20201175T1 (OSRAM)
HU (1) HUE051634T2 (OSRAM)
IL (1) IL265298B (OSRAM)
JO (1) JOP20190052A1 (OSRAM)
LT (1) LT3515910T (OSRAM)
MA (1) MA46268B1 (OSRAM)
MX (2) MX381898B (OSRAM)
PE (1) PE20190909A1 (OSRAM)
PH (1) PH12019500615A1 (OSRAM)
PL (1) PL3515910T3 (OSRAM)
PT (1) PT3515910T (OSRAM)
RS (1) RS60764B1 (OSRAM)
SI (1) SI3515910T1 (OSRAM)
SM (1) SMT202000481T1 (OSRAM)
SV (1) SV2019005857A (OSRAM)
TW (1) TW201813967A (OSRAM)
UA (1) UA123558C2 (OSRAM)
WO (1) WO2018055040A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
KR102851010B1 (ko) * 2019-04-10 2025-08-26 난징 젱시앙 파마슈티칼스 컴퍼니 리미티드 포스파티딜이노시톨 3-키나제 저해제
JP7665534B2 (ja) 2019-06-04 2025-04-21 アーカス バイオサイエンシーズ インコーポレイテッド 2,3,5-三置換ピラゾロ[1,5-a]ピリミジン化合物
CN114258393B (zh) * 2020-07-21 2024-11-22 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2022023456A1 (en) 2020-07-29 2022-02-03 Astrazeneca Ab Pharmaceutical compositions comprising nano embedded microparticles and methods of use
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117605T2 (de) * 2000-12-21 2006-12-07 Bristol-Myers Squibb Co. Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1893607A4 (en) * 2005-06-09 2010-07-21 Merck Sharp & Dohme CHECKPOINT KINASE INHIBITORS
JP5561702B2 (ja) * 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Pi3キナーゼ調節剤および使用方法
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
JP2014528451A (ja) 2011-10-04 2014-10-27 ギリアード カリストガ エルエルシー Pi3kの新規キノキサリン阻害剤
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
JP6371838B2 (ja) 2013-07-02 2018-08-08 ライゼン・ファーマシューティカルズ・エスアー Pi3kタンパク質キナーゼ阻害剤、特に、デルタ及び/またはガンマ阻害剤
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
EP3160968B1 (en) 2014-06-27 2018-10-31 Rhizen Pharmaceuticals S.A. Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases

Also Published As

Publication number Publication date
PT3515910T (pt) 2020-09-16
CO2019003440A2 (es) 2019-04-12
EP3515910A1 (en) 2019-07-31
ES2818583T3 (es) 2021-04-13
US10961236B2 (en) 2021-03-30
AU2017331940A1 (en) 2019-05-02
IL265298B (en) 2020-09-30
EA201990664A1 (ru) 2019-08-30
US20200308164A1 (en) 2020-10-01
TW201813967A (zh) 2018-04-16
SV2019005857A (es) 2019-05-06
SI3515910T1 (sl) 2020-09-30
WO2018055040A1 (en) 2018-03-29
PL3515910T3 (pl) 2021-02-22
CA3036304A1 (en) 2018-03-29
UA123558C2 (uk) 2021-04-21
MX381898B (es) 2025-03-13
MA46268A (fr) 2019-07-31
DOP2019000073A (es) 2019-04-15
HUE051634T2 (hu) 2021-03-01
PE20190909A1 (es) 2019-06-26
AR109706A1 (es) 2019-01-16
MA46268B1 (fr) 2020-08-31
JP6765516B2 (ja) 2020-10-07
PH12019500615A1 (en) 2019-06-03
EP3515910B1 (en) 2020-07-15
AU2017331940B2 (en) 2020-03-12
EA036176B1 (ru) 2020-10-09
JP2019529445A (ja) 2019-10-17
KR20190049867A (ko) 2019-05-09
HRP20201175T1 (hr) 2020-11-13
US20210246130A1 (en) 2021-08-12
LT3515910T (lt) 2020-10-12
CN109715623A (zh) 2019-05-03
SMT202000481T1 (it) 2020-11-10
KR102226098B1 (ko) 2021-03-09
RS60764B1 (sr) 2020-10-30
BR112019004719A2 (pt) 2019-05-28
CL2019000707A1 (es) 2019-05-31
JOP20190052A1 (ar) 2019-03-21
CR20190200A (es) 2019-06-07
MX2021004748A (es) 2021-06-08
ECSP19027780A (es) 2019-04-30
MX2019003194A (es) 2019-06-17
IL265298A (en) 2019-05-30
CY1123346T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
DK3515910T3 (da) 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma
DK3317286T3 (da) Cykliserede sulfamoylarylamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
LT3464272T (lt) Nauji heterocikliniai dariniai, naudingi kaip shp2 inhibitoriai
DK3154957T3 (da) Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
DK3464284T3 (da) Mikrobiocide thiazolderivater
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3536685T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser og anvendelse deraf som irak4 inhibitorer
DK3294738T3 (da) Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
DK3630724T3 (da) Substituerede indolinderivater som inhibitorer af virusreplikation af denguevirus
DK3307727T3 (da) Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft
DK3461812T3 (da) N-(5-(biphen-4-ylmethyloxy)pentyl)-substituerede iminosukre som inhibitorer af glucosylceramidsyntase
DK3350163T3 (da) Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
DK3601225T3 (da) Substituerede indolinderivater som inhibitorer af denguevirus-replikation
DK3436435T3 (da) Substituerede indolderivater som inhibitorer af replikation af denguevirus
DK3436437T3 (da) Substituerede indolinderivativer som dengue¬virus-replikations¬hæmmere
DK3310784T3 (da) Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3551625T3 (da) Heterocykliske inhibitorer af mct4
DK3643713T3 (da) Heterocykliske kinaseinhibitorer og deres anvendelse
DK3244886T3 (da) Indolderivater som inhibitorer af dengue virus-replikation
DK3481819T3 (da) Forbindelser og anvendelse deraf til reducering af urisyreniveauer
DK3292105T3 (da) Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid